Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BioElectronics inks distribution agreement with KT Health
Dec. 15, 2020 7:33 AM ETBioElectronics Corporation (BIEL)By: Khyathi Dalal, SA News Editor
BioElectronics (OTCPK:BIEL) executed an OEM agreement with KT Health for bringing its innovative pain management devices to encompass retail and e-commerce distribution across North America, and other additional key international markets.
The agreement incorporates BioElectronics' ActiPatch technology into KT Health’s KT Recovery + product line, which will be marketed under the proprietary trade name KT Recovery+ Wave.
KT Health will leverage BioElectronics' FDA 510(k) clearance to market, promote, and distribute the devices for the treatment of general musculoskeletal pain.
Under this agreement, BioElectronics will stop active promotion of the brand name ActiPatch in North America while existing channel partners in U.S. will continue promoting the brand name.
The post is BS related to Kelly and Biel
Longs-understand-the-difference-between-Tens-and Pemf LMAO
LMAO A Lot Of BS Misinformation Being Posted Related To Biel, No Stopping The Momentum Go Biel
mtoronto 11/26/20
Hi Everybody
I just want to mention one thing to ponder over. I mentioned in my last post that you will see competitive brands in the market that may be our competition but in fact they are BIEL products.
It's safe to say by Rick's wording "Our current plan is to discontinue North American sales under the brand name of ActiPatch by the end of the year. OTC sales in North America will be under the brand names of our marketing partners- essentially a license and supply agreement"
This is a very strong statement by Rick, so expect huge news on licensing agreements which include a licensing fee and huge partners coming on board.
Yes, my friends, no more Act-Patch name in the North American markets.
Most if not all products using PEMF will probably say powered by-????
Stay turned for huge news in the coming months.
One Thing I Know All The MisInformation In Posts Related To Biel Will CHANGE NOTHING GO BIEL
Great to have Richard Staelin, Ph.D. Chairman of Biel and a bunch are jealous of him LOL OH well
Funny we get posts that do not know the difference between Tens and Actipatch, thinking Tens is a PEMF device LMAO
THANKSGIVING LETTER FROM THE CHAIRMAN
November 26th, 2020
Dear Shareholders,
It has been a few months since I wrote a Chairman’s letter laying out our new OEM strategy that we implemented just about a year ago. The purpose of this letter is to document some of our accomplishments over the last 12 months and to share with you some of the major events that have occurred, or we believe will be occurring in the early part of 2021.
Sales
Soon after the management reorganization, our sales team got on the phones to re-establish relationships with firms that the Company had talked to over the last few years. After a few false starts, the team re-engaged with three firms with interest of selling our medical devices into the domestic OTC market. The first was Scott Specialty. This firm was in the process of developing specialty wraps for DonJoy. Scott placed their first order in August and we anticipate that the final units associated with this initial order will be delivered by early December. (DonJoy is already selling units online and we are told they will be placing units in brick and mortar outlets next month.) We are anticipating a new order from Scott just after the new year.
Two other firms have also placed orders to sell our device in the domestic OTC market. However, they have yet to distribute their products into retail and thus we are not able to identify them. With this noted, both will be receiving delivery of units in December and thus we anticipate booking sales to these customers in fourth quarter 2020. (These two customers anticipate selling into their retail markets in first quarter 2021.)
Internationally, we landed a contract with Adcock, a large firm in South Africa. Adcock is now in the process of registering the product and first sales to them should occur in early 2021. In addition, now that we have re-acquired our CE mark, we are able to reopen communications with our international distributors. We anticipate (or have already received) new orders from Romania, Italy, Australia, Sweden, the UK, and Spain. These sales should be booked in 4th quarter 2020 or 1st quarter 2021. In addition, one of our major domestic customers has been talking to us about also acquiring distribution internationally. These talks will probably continue into 2021.
Finally, we are in the early stages of selling into the medical professional channel with our RecoveryRx product. The plan is to use a 300+ salesforce of independent reps. This salesforce is being set up by Medi-Launch, a firm that has expertise in forming medical salesforce teams and launching new medical products. We have already signed up over 275 salespeople who have distributed more than 1500 samples to surgeons and other medical professionals. These samples allow the medical professionals evaluate our product for post-surgical pain and wound care, the claim associated with our non-OTC 510 (k). A few sales have already been booked and ultimately, we believe this channel of distribution could account for as much as 15% of our total sales volume.
Although I suspect most of you are primarily interested in the above information on sales (and ultimately profits) I would briefly like to mention the support activities that have occurred over this time period to make all these sales happen.
Modifying the product design and building up production capability. One of our customers wanted major design changes to our 720 hour device. This required extensive internal design changes to the device and modifications of the manufacturing processes. In addition this customer wanted to completely redesign the packaging. Coordinating all these changes resulted in extensive communications with the customer’s design team (and their top management) as well as nightly calls to our overseas manufacturer. There were surprisingly few bumps in the road and we are well on the way to fulfill their order. Importantly, this experience has greatly enhanced our core capabilities in product design and manufacturing.
Regulatory issues
We started off the year with significant regulatory issues. The regulatory team worked tirelessly with the firm, NEMCO, to get re-certified. It was a long battle, but we received notification in early November. This certification was critical as it allows us to again sell internationally.
I wish this was the only regulatory issue that we faced this year. We also need to get another certification, called MDSAP. This certification will allow us to sell in Canada and Australia among other countries. The short story is that we are well positioned to complete all the audits needed for certification by late January 2021. In the process we have developed a totally new inventory tracking system needed to augment our quality control processes. Development of this system has been a total team effort.
Other issues—Salesforce sales, Rebranding and R&D
Three other efforts that are currently in progress deserve mention. The first involves developing systems to handle sales through our new salesforce network and new marketing and training materials to support this salesforce. The training materials have been developed and are being used in numerous training zoom meetings, where we educate the independent sales reps on how to present the information concerning our device.
This new emphasis on selling our Rx product has also led us to revise our branding strategy so as to better differentiate the RecoveryRx device from the ActiPatch device. This rebranding is particularly important because the sales prices for these two devices are quite different. Our current plan is to discontinue North American sales under the brand name of ActiPatch by the end of the year. OTC sales in North America will be under the brand names of our marketing partners- essentially a license and supply agreement. We will retain the ActiPatch brand for units embedded into an appliance and sold under the appliance manufacturer’s brand name as “Powered by ActiPatch.”
Last, but not the least, we have made good progress with our R&D efforts. We started basic research to ascertain how our device affects brain waves. This project could open up the doors to solving numerous other diseases/ailments. We have also received notification that our neck study paper has been accepted for publication. The results reported in this paper not only show efficacy of the device over NSAID’s but also strong evidence supporting our claim that our device works via central sensitization. This latter finding is very useful when talking to medical professionals, since they want to know the “mechanism of action”, i.e., why our device works.
Summary
In summary, it has been a busy and productive year. The Company is moving in the right direction. Numerous new systems have been developed to support our new OEM strategy. Our core capabilities of R&D and expertise in designing and manufacturing Pulsed Short Wave Therapy devices have increased. The forecast for the next year has us above breakeven sales. Meeting these projections will not be easy, but it is doable. I am sure there will be some bumps, but the BIEL team will rise to the challenge and come out stronger. Thank you for your continued support, have a great Thanksgiving and stay safe.
Richard Staelin, Ph.D.
Chairman of the Board
BY MM's
BioElectronics Corp @BielCorp
Getting some attention for the hard work everyone has done this past year. #brickbybrick #teambiel #waituntilyouseewhatelsewehavedone
https://microcapdaily.com/actipatch-recoveryrx-the-rise-of-bioelectronics-corp-otcpink-biel/128644/
LMAO I KNOW Keith Nalepka @keith_nalepka With so many positive things happening, 4th qtr sales, after 6 weeks, exceed total 3 quarter sales. OEM plan executing. RecoveryRx ahead of plan, international growth through key partners. Making strides towards 2021 profitability. #teamBIEL #brickbybrick
@BielCorp
10:40 AM · Nov 18, 2020·Twitter Web App
Biel-has-more-than-$307,774-in-sales-in-the-first-6-weeks-of the 4th Quarter. Roll On Team Biel
What is PEMF good for?
By inducing a mild electrical magnetic current into damaged cells, PEMF therapy slows or stops the release of pain and inflammatory mediators, increases blood flow of the cells, and re-establishes normal cell interaction. With reduced inflammation, pain decreases, energy increases, and faster tissue healing occurs.”Jan 24, 2019
Does NASA use PEMF? Studies have shown that the PEMF given off by the Earth is equally as important to human health as food, water, sleep, and sunlight. Pulsed Electromagnetic Field devices were originally used by NASA to maintain the health of astronauts in orbit.
Will be a great day for Biel to leave this pink bs and mm's manipulation
I believe the 3rd Q only in 1st 6 weeks of the 4th Q. Big Time Sales are rolling on.
VP-Sales-STATING-This-BOOM_BOOM-With-so-many-positive-things-happening-4th-qtr-sales-after-6-weeks, exceed total 3 quarter sales. OEM plan executing. RecoveryRx ahead of plan, international growth through key partners. Making strides towards 2021 profitability. #teamBIEL #brickbybrick
@BielCorp
Keith Nalepka
@keith_nalepka
10:40 AM · Nov 18, 2020·Twitter Web App
Do not use TENS Here are 10 TENS Unit side effects to be aware of:
1. Burn Marks
2. Skin Irritation
3. Muscle Twitching
4. Damage to Open Wounds
5. Potential Fetal Harm
6. Muscle Pain
7. Muscle Soreness
8. Facial Nerve Damage
9. Loss of Muscular Control
10. Unpleasant Electric Shocks to the Skin
FUNNY-BULL-CRAP-TENS-IS-NOT-PEMF-STAY-ON-TOPIC-ACTIPATCH IS PEMF
BOOM_BOOM-With-so-many-positive-things-happening-4th-qtr-sales-after-6-weeks, exceed total 3 quarter sales. OEM plan executing. RecoveryRx ahead of plan, international growth through key partners. Making strides towards 2021 profitability. #teamBIEL #brickbybrick
@BielCorp
Keith Nalepka
@keith_nalepka
10:40 AM · Nov 18, 2020·Twitter Web App
Shop Products Scott Specialties All Products (587 Items) Damn McKesson is carrying a lot of Scoot's Products
McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools. The company had revenues of $231.1 billion in 2020. Wikipedia
Stock price: MCK (NYSE) $173.64 -10.11 (-5.50%)
Nov 17, 4:02 PM EST - Disclaimer
Headquarters: Irving, TX
CEO: Brian S. Tyler (Apr 1, 2019–)
Revenue: 214.3 billion USD (2019)
Number of employees: 80,000 (2019)
https://mms.mckesson.com/catalog?node=5555121
Biel's management team is keeping their goals in sight and working to achieve them for the company and shareholders. THE BEST IS YET TO COME, GO BIEL. Biel's Products Helping People Who Are Suffering From Pain And Other Medical Issues.
THE-COME-BACK-GANG-AMAZING-IN-THE-MIDDLE-OF-A-WORLDWIDE-DEADLY PANDEMIC. A major increase in sales over 2nd Q and beat the same Q 2019. ROLL ON TEAM BIEL ROLL ON
Keith Nalepka @keith_nalepka
52m
Great unsolicited piece!! We have all worked hard this last year in challenging times to deliver on what was promised! This is our time, well positioned, buckle up! Best is yet to come. #brickbybrick #teamBIEL #loadingthebases
The Company recently reported it already has 250+ Reps in the field selling RecoveryRX. BIEL operates in the booming chronic pain market which is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers.
MICROCAP-DAILY-ActiPatch-RecoveryRx-the-Rise-of BioElectronics Corp. (OTCPINK: BIEL)
BY JACOB WATSON ON NOVEMBER 16, 2020
MEDIA & TECHNOLOGY, MICRO CAP INSIDER, STREET WATCH
BioElectronics Corp. (OTCPINK: BIEL) is making a strong move up the charts in recent weeks on heavy trading as the Company reports it has received the CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA).
This represents the latest in a series of recent wins for BioElectronics. The CE mark allows the Company to resume fulfilling substantial orders for existing international partners, and close pending deals that were contingent on the CE mark. BioElectronics has signed long term contracts with, and received initial stocking orders and cash deposits from, three major companies. These initial orders total more than 120,000 ActiPatch devices. The Company recently reported it already has 250+ Reps in the field selling RecoveryRX. BIEL operates in the booming chronic pain market which is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers.
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. The Company’s core capabilities are its deep knowledge and experience in Pulsed Short Wave Therapy (PSWT) technology which is the use of non-thermal, high-frequency electromagnetic fields for therapeutic purposes. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.In February 2017, BioElectronics received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to plantar fasciitis of the heel, and osteoarthritis of the knee. On July 1, 2019 the Company announced that it has received market clearance from the United States Food and Drug Administration (US FDA) for its RecoveryRx® medical device, for the treatment of postoperative pain. In February 2020, BioElectronics obtained a new 510(k) clearance from the U.S. FDA, granting over-the-counter marketing clearance for the drug-free ActiPatch® medical device, to cover all musculoskeletal pain complaints.
This paves the way for new products to treat all medical claims for musculoskeletal pain, including in the back, knee, hips, wrists, elbow, and ankle. The chronic pain market is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers.
The Company’s medical devices modulate the body’s nerve activity to dampen the pain perception, which reduces drug use. RecoveryRx will be an ideal choice in reducing postoperative pain and exposure to long-term effects of opioid/NSAID therapy. Ken McLeod, PhD. Director of Clinical Science and Engineering Research, Binghamton State University of New York, explains in a short video how the technology and ActiPatch works.
Management believes the technology has the potential to become the standard of care throughout the healthcare continuum across the OTC and healthcare markets. BioElectronics’ technology offers significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications. BIEL plans to act as the original equipment manufacturer (OEM) which has allowed the Company to establish several new distributing relationships and develop new product offerings.
Recently BioElectronics executed a commercial partnership agreement with Scott Specialties Inc to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy® Advantage product line. This commercial partnership leverages the ActiPatch’s broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO’s DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap,” powered by ActiPatch”.
On November 12 BIEL announced it has received the CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx® Pulsed Shortwave Therapy (PSWT) medical devices. The ActiPatch is indicated for the treatment of general musculoskeletal/soft-tissue pain, while the RecoveryRx is indicated for the treatment of postoperative pain. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. The certification for the CE mark is valid until May 2024, and the Company’s updated quality management system will ensure prompt recertification.
BIEL is an exciting stock in small caps with a long history of big moves in recent years. Currently on the move northbound as the Company reports it has received the CE Mark for its ActiPatch® indicated for the treatment of general musculoskeletal/soft-tissue pain and RecoveryRx® Pulsed Shortwave Therapy (PSWT) indicated for the treatment of postoperative pain medical devices. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA). This represents the latest in a series of recent wins for BioElectronics. The CE mark allows the Company to resume fulfilling substantial orders for existing international partners, and close pending deals that were contingent on the CE mark. BioElectronics has signed long term contracts with, and received initial stocking orders and cash deposits from, three major companies. These initial orders total more than 120,000 ActiPatch devices. The Company recently reported it already has 250+ Reps in the field selling RecoveryRX. BIEL operates in the booming chronic pain market which is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers.
Disclosure: we hold no position in BIEL either long or short and we have not been compensated for this article
Release #:812-195312-rl-1141231:
MICROCAP DAILY
ActiPatch, RecoveryRx; the Rise of BioElectronics Corp. (OTCPINK: BIEL)
BY JACOB WATSON ON NOVEMBER 16, 2020
MEDIA & TECHNOLOGY, MICRO CAP INSIDER, STREET WATCH
Post Views: 146
BioElectronics Corp. (OTCPINK: BIEL) is making a strong move up the charts in recent weeks on heavy trading as the Company reports it has received the CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA).
This represents the latest in a series of recent wins for BioElectronics. The CE mark allows the Company to resume fulfilling substantial orders for existing international partners, and close pending deals that were contingent on the CE mark. BioElectronics has signed long term contracts with, and received initial stocking orders and cash deposits from, three major companies. These initial orders total more than 120,000 ActiPatch devices. The Company recently reported it already has 250+ Reps in the field selling RecoveryRX. BIEL operates in the booming chronic pain market which is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers.
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. The Company’s core capabilities are its deep knowledge and experience in Pulsed Short Wave Therapy (PSWT) technology which is the use of non-thermal, high-frequency electromagnetic fields for therapeutic purposes. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.In February 2017, BioElectronics received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to plantar fasciitis of the heel, and osteoarthritis of the knee. On July 1, 2019 the Company announced that it has received market clearance from the United States Food and Drug Administration (US FDA) for its RecoveryRx® medical device, for the treatment of postoperative pain. In February 2020, BioElectronics obtained a new 510(k) clearance from the U.S. FDA, granting over-the-counter marketing clearance for the drug-free ActiPatch® medical device, to cover all musculoskeletal pain complaints.
This paves the way for new products to treat all medical claims for musculoskeletal pain, including in the back, knee, hips, wrists, elbow, and ankle. The chronic pain market is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers.
The Company’s medical devices modulate the body’s nerve activity to dampen the pain perception, which reduces drug use. RecoveryRx will be an ideal choice in reducing postoperative pain and exposure to long-term effects of opioid/NSAID therapy. Ken McLeod, PhD. Director of Clinical Science and Engineering Research, Binghamton State University of New York, explains in a short video how the technology and ActiPatch works.
Management believes the technology has the potential to become the standard of care throughout the healthcare continuum across the OTC and healthcare markets. BioElectronics’ technology offers significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications. BIEL plans to act as the original equipment manufacturer (OEM) which has allowed the Company to establish several new distributing relationships and develop new product offerings.
Recently BioElectronics executed a commercial partnership agreement with Scott Specialties Inc to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy® Advantage product line. This commercial partnership leverages the ActiPatch’s broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO’s DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap,” powered by ActiPatch”.
On November 12 BIEL announced it has received the CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx® Pulsed Shortwave Therapy (PSWT) medical devices. The ActiPatch is indicated for the treatment of general musculoskeletal/soft-tissue pain, while the RecoveryRx is indicated for the treatment of postoperative pain. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. The certification for the CE mark is valid until May 2024, and the Company’s updated quality management system will ensure prompt recertification.
BIEL is an exciting stock in small caps with a long history of big moves in recent years. Currently on the move northbound as the Company reports it has received the CE Mark for its ActiPatch® indicated for the treatment of general musculoskeletal/soft-tissue pain and RecoveryRx® Pulsed Shortwave Therapy (PSWT) indicated for the treatment of postoperative pain medical devices. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA). This represents the latest in a series of recent wins for BioElectronics. The CE mark allows the Company to resume fulfilling substantial orders for existing international partners, and close pending deals that were contingent on the CE mark. BioElectronics has signed long term contracts with, and received initial stocking orders and cash deposits from, three major companies. These initial orders total more than 120,000 ActiPatch devices. The Company recently reported it already has 250+ Reps in the field selling RecoveryRX. BIEL operates in the booming chronic pain market which is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers.
Disclosure: we hold no position in BIEL either long or short and we have not been compensated for this article
It is a private group BioElectronics Shareholders BIEL on facebook try again can be slow
On Biel's shareholder facebook page
Ronald Hess
4h ·
Aren’t the financials supposed to be out Monday?
Comments
Kelly Whelan
I have been informed by Brian Flood that he is working to meet the deadline, but he is likely going to be late....
· Reply · 4h
Ronald Hess
Kelly Whelan Sounds great I’m excited to hear what they are
· Reply · 4h
Kelly Whelan
Ronald Hess they are definitely better than Q2!
· Reply · 3h
Ronald Hess
Kelly Whelan That is great news
· Reply · 3h
Kelly Whelan
Ronald Hess it would be hard to be worse...damn pandemic!
· Reply · 3h
Ronald Hess
Kelly Whelan lol so true !!!!!
· Reply · 3h
Write a reply...
Gladys Funches
I very hopeful. A delay is not a denial.
· Reply · 4h
Kelly Whelan
I hope he is able to knock them out over the weekend and I will make myself available to get them out. We will publish as soon as they are complete and I have reviewed them.
· Reply · 4h
John Morris
Who can ask for more?
· Reply · 3h
Kelly Whelan
John Morris actually I am not happy that Brian has said he thinks he will be late. We do pay for their services!
Maybe one day we will be off this PINK crap and it will solve a bunch of BS related to Biel.
BioElectronics Earns CE Mark for the ActiPatch and RecoveryRx -- Drug-Free Pain Therapy Devices
Opens the Sales Market for 33+ Additional Countries
FREDERICK, MD, Nov. 12, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that it has received the CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx® Pulsed Shortwave Therapy (PSWT) medical devices.
The ActiPatch is indicated for the treatment of general musculoskeletal/soft-tissue pain, while the RecoveryRx is indicated for the treatment of postoperative pain. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark.
Keith Nalepka, VP Sales and Marketing for BioElectronics, said: “This is the latest in a series of wins for the Company. The CE mark will allow us to resume fulfilling substantial orders for existing international partners, and close pending deals that were contingent on the CE mark. We are excited that 2021 will be a great year of sales for the Company.”
The certification for the CE mark is valid until May 2024, and the Company’s updated quality management system will ensure prompt recertification.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Therapy for postoperative pain and chronic wound care.
Forward Looking Statements
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Paul Knopick
9402623584
pknopick@eandecommunications.com
Another major win! CE mark finalized. Great team effort! Frees up large sales agreements contingent upon. Great execution!! BioElectronics Corp liked
Keith Nalepka
@keith_nalepka
·
17m
TWO Future Markets That Will Help Save Lives Wound Treatment and Prostate Treatment GO BIEL
Effect of Pulsed Electromagnetic Field Therapy on Prostate Volume and Vascularity in the Treatment of Benign Prostatic Hyperplasia: A Pilot Study in a Canine Model
The 3 weeks of PEMF produced a significant reduction in prostatic volume (average 57%) without any interference with semen quality, testosterone levels or libido.
Another giant market for Biel, just need money to do clinical trials and help save lives
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145661/
They would work great for prostate treatment, I have been using Actipatch for about 7 years to treat my prostate. Since Biel an email, yesterday to explore the use to treat prostate cancer
In 2018, 1,276,106 new cases of prostate cancer were registered worldwide, representing 7.1% of all cancers in men [1]. Prostate cancer incidence rates are highly variable worldwide. The age-standardized rate (ASR) was highest in Oceania (79.1 per 100,000 people) and North America (73.7), followed by Europe (62.1).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497009/
McKesson sales their product
https://mms.mckesson.com/product/703050/Scott-Specialties-SA0249-WHI-XL
I have a few at .0003, I'm thinking in the near future .009 and more.
Attn those who suffer from prostate problems, found this holder on Mckesson website made by Scott. Just stick Actipatch in the holder. It should help your prostate, it has done wonders for mine.
https://mms.mckesson.com/product/703050/Scott-Specialties-SA0249-WHI-XL